trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

PCSK9 inhibitors block a protein called PCSK9, which helps the liver remove LDL cholesterol from the blood.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that PCSK9 inhibitors block a protein called PCSK9, which helps the liver remove LDL cholesterol from the blood?

Yes. PCSK9 inhibitors successfully lower LDL cholesterol by blocking the PCSK9 protein, which normally promotes the degradation of low-density lipoprotein receptors in the liver.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently confirm that PCSK9 promotes the degradation of low-density lipoprotein receptors (LDLR) in the liver and that inhibiting PCSK9 prevents this degradation, helping the liver remove LDL cholesterol from the blood.

Evidence for · 3
Transport pathways across the blood-brain barrier for waste clearance and drug delivery.
2026
Get citation
LS, G. & CU, P. (2026). Transport pathways across the blood-brain barrier for waste clearance and drug delivery.. doi.org. https://doi.org/10.1186/s12987-026-00812-7

See more details
More for · 2
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.
2026
Get citation
RB, V., G, O., AM, B., H, Y., J, K., J, B., T, H., L, B., E, T. C., A, A., CR, U., A, R., D, C., J, L., A, G., L, T., P, G., A, B., E, H., T, M., M, R., A, H., B, H., M, S., V, K., S, G., MC, M., D, L., & JB, R. (2026). Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.. doi.org. https://doi.org/10.1161/circulationaha.125.075973

PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications.
2026
Get citation
JDJ, W., AYT, T., B, X., Y, C., ZD, Z., BJ, T., LL, C., E, R., & EK, T. (2026). PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications.. doi.org. https://doi.org/10.1186/s40035-026-00568-y

What does the evidence say?

The retrieved papers consistently confirm that PCSK9 promotes the degradation of low-density lipoprotein receptors (LDLR) in the liver and that inhibiting PCSK9 prevents this degradation, helping the liver remove LDL cholesterol from the blood.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work